Editorial: Incretin-based therapies: economic sustainability and health impact in the global management of metabolic syndrome

Alessio Provenzani, Tanja Mueller, Alessandro Mattina

Open source

DOI
10.3389/fphar.2026.1954325
Published
2026-08-17
Container
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1954325,
  title = {Editorial: Incretin-based therapies: economic sustainability and health impact in the global management of metabolic syndrome},
  author = {Alessio Provenzani and Tanja Mueller and Alessandro Mattina},
  year = {2026},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2026.1954325},
  url = {https://doi.org/10.3389/fphar.2026.1954325}
}

RIS

TY  - JOUR
TI  - Editorial: Incretin-based therapies: economic sustainability and health impact in the global management of metabolic syndrome
AU  - Alessio Provenzani
AU  - Tanja Mueller
AU  - Alessandro Mattina
PY  - 2026
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1954325
UR  - https://doi.org/10.3389/fphar.2026.1954325
ER  - 

APA

Provenzani, A., Mueller, T., & Mattina, A. (2026). Editorial: Incretin-based therapies: economic sustainability and health impact in the global management of metabolic syndrome. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1954325

Source records